Technology & Innovation that Drives Retention
Powering an integrated, personalized, and holistic approach to digital connectivity
Validated ROI and Patient Value at Scale
Just-in-Time-Interventions (JITI)™
Precise and personalized advanced technology
Medisafe Maestro
An integrated patient experience, reimagined
Care Integration Engine
Technology that revolutionizes patient support
Real-World Data Insights
Exclusive insights from real patient behaviors
Connected Health Platform
Medication Engagement Technology
Built on a foundation of unmatched usability and commercial adoption at its core, Medisfe’s Enterprise Connected Health Platform is the only completely configurable and rapid-ready platform technology to create, launch and maintain digital health solutions with precision and efficiency.
Digital Drug Companion
Medication Engagement Platform
Patients receive complete treatment management through a combination of advanced technology and expert knowledge. Connect patients with an innovative digital platform that drives medication engagement, integrates human support and delivers a holistic care experience.
Download Medisafe:
Just-in-Time-Interventions (JITI™)
Powering the Medisafe platform with advanced technology that drives personalized interventions
Medisafe Maestro
Digitize patient journeys to optimize patient engagement and brand-specific support
Care Integration Engine
Interoperable technology to integrate care and coordination teams into patient journeys
A comprehensive look at patient segments to inform future treatment journeys
Latest From Medisafe
Navigating Patient Adherence in Hunter Syndrome with Medisafe
The Precision Imperative: How Medisafe Empowers Denali Therapeutics and the Hunter Syndrome Community Amidst Tividenofusp Alfa’s Arrival The landscape of rare disease treatment is undergoing a profound transformation, nowhere more acutely felt than in conditions like Hunter Syndrome (Mucopolysaccharidosis type II or MPS II). With the potential arrival of novel, transformative therapies such as Denali Therapeutics’ Tividenofusp alfa—an investigational fusion protein designed to enhance…